Brolucizumab
Pre-clinicalTerminated 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neovascular Age-related Macular Degeneration (nAMD)
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Trial Timeline
May 10, 2021 โ Feb 16, 2024
NCT ID
NCT04764656About Brolucizumab
Brolucizumab is a pre-clinical stage product being developed by Novartis for Neovascular Age-related Macular Degeneration (nAMD). The current trial status is terminated. This product is registered under clinical trial identifier NCT04764656. Target conditions include Neovascular Age-related Macular Degeneration (nAMD).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05959304 | Approved | Active |
| NCT04774926 | Approved | Completed |
| NCT04679935 | Approved | Completed |
| NCT04697953 | Phase 3 | Withdrawn |
| NCT04764656 | Pre-clinical | Terminated |
| NCT04597632 | Phase 3 | Completed |
| NCT04543331 | Pre-clinical | Completed |
| NCT05111743 | Pre-clinical | Completed |
| NCT05082415 | Pre-clinical | Completed |
| NCT05037396 | Pre-clinical | Completed |
Competing Products
20 competing products in Neovascular Age-related Macular Degeneration (nAMD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | 33 |
| Avacincaptad Pegol + Avastin + Lucentis + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol + Lucentis | Astellas Pharma | Phase 2 | 52 |
| KHK4951 + Aflibercept Injection | Kyowa Kirin | Phase 2 | 52 |
| Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab Control | AbbVie | Phase 3 | 77 |
| Ranibizumab + Local Steroid + Topical Steroid | AbbVie | Phase 2 | 52 |
| Lucentis | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Approved | 85 |
| brolucizumab + ranibizumab + aflibercept | Novartis | Pre-clinical | 23 |
| Beovu | Novartis | Pre-clinical | 23 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| Intraviteal Ranibizumab 0.5mg | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |